Market revenue in 2023 | USD 195.0 million |
Market revenue in 2030 | USD 251.0 million |
Growth rate | 3.7% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.92% in 2023. Horizon Databook has segmented the Italy attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of diseases is expected to drive market growth. Stimulant drugs for ADHD are more effective than nonstimulant medications. Methylphenidate is considered the first choice of stimulant drug for the treatment of patients with ADHD.
Instead, nonpharmacological treatments for ADHD are not as effective as pharmacological treatments for ADHD but are commonly suitable to solve issues that arise after medication has been optimized.
Based on an article published by MDPI in 2021, around 734 patients received a medicine prescription, 679 (16.6%) of them methylphenidate (0.5mg to 80mg daily), of those 21 (0.5%) together with another drug (i.e., aripiprazole, risperidone, sertraline, lorazepam, alprazolam, fluvoxamine, haloperidol, clomipramine, & delorazepam), 23 (0.6%) atomoxetine (10mg to 60mg daily), and 53 (1.3%) other psychotropic drugs in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into Italy attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account